Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
View Patent ↗The disclosed method provides a novel approach of generating antigen-specific Immunological Memory in a subject which consists primarily of extracting and purifying monocytes, naive T and B lymphocytes from a subject and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are generated with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject. In embodiments, one will see a vaccine approach wherein said vaccine excludes the inoculation of attenuated or killed whole pathogens, where inoculation of said vaccine does not illicit an immune response upon inoculation, and where said vaccine excludes chemicals such as thimerosal, formaldehyde, and aluminum which is all shunned by anti-vaccinators.
1. A method for generating immunological memory against influenza virus in a subject, comprising:
(a) purifying naïve T and B lymphocytes from the subject, wherein the subject is an autologous donor,
(b) culturing and pulsing said naïve T and B lymphocytes with influenza virus antigens in the presence of antigen-presenting cells loaded with influenza virus antigens and cytokines, thereby generating anti-influenza antigen-specific memory T and B lymphocytes,
(c) genetically modifying said anti-influenza antigen-specific memory B lymphocytes to incorporate exogenous nucleic acid sequences encoding an anti-influenza broadly neutralizing antibody binding influenza antigen, and
(d) administering said anti-influenza antigen-specific memory T lymphocytes generated in step (b) and anti-influenza antigen-specific memory B lymphocytes, generated in step (c) to said subject.
2. The method of claim 1 , wherein the anti-influenza antigen-specific immune memory T lymphocytes are CD4 T lymphocytes, and/or CD8 T lymphocytes.
3. The method of claim 1 , wherein genetically modifying said anti-influenza antigen-specific memory B lymphocytes comprises CRISPR (Clustered Regularly interspaced Short Palindromic Repeats) Cas 9 incorporation of exogenous nucleic acid sequences encoding an anti-influenza broadly neutralizing antibody comprising at least two of SEQ ID NO: 1-8.